# Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression

Study · id `cardio:ct-nct07715279` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07715279](<https://clinicaltrials.gov/study/NCT07715279>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07715279

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 238 participants.

## Technical summary

Registry record NCT07715279. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-24 (actual); primary completion 2029-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 238 participants (planned count; ClinicalTrials.gov record NCT07715279, source copy `cardio:ctgov-nct07715279-2026-09-25`, retrieved 2026-10-26)
- Started: 2026-09-24 (actual) (ClinicalTrials.gov record NCT07715279, source copy `cardio:ctgov-nct07715279-2026-09-25`, retrieved 2026-10-26)
- Primary completion: 2029-10-31 (anticipated) (ClinicalTrials.gov record NCT07715279, source copy `cardio:ctgov-nct07715279-2026-09-25`, retrieved 2026-10-26)
- Completion: 2029-11-30 (anticipated) (ClinicalTrials.gov record NCT07715279, source copy `cardio:ctgov-nct07715279-2026-09-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07715279, source copy `cardio:ctgov-nct07715279-2026-09-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07715279-2026-09-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression
- Acronym: VERIFICATION
- Condition: Calcific Aortic Valve Disease
- Condition: AORTIC VALVE DISEASES
- Condition: Aortic Valve Stenosis
- Intervention (Drug): Vericiguat (BAY1021189)
- Intervention (Drug): Placebo
- Lead sponsor: West China Hospital
- Lead sponsor class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: West China Hospital (`cardio:org-west-china-hospital`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: 58ff36526e8430abf02c5f09cfc8d9d492edda097cca0f2398e12017495feffa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
